IBDEI33E ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,49378,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49378,1,3,0)
;;=3^Frontotemporal Dementia NEC
;;^UTILITY(U,$J,358.3,49378,1,4,0)
;;=4^G31.09
;;^UTILITY(U,$J,358.3,49378,2)
;;=^329916
;;^UTILITY(U,$J,358.3,49379,0)
;;=G20.^^187^2447^24
;;^UTILITY(U,$J,358.3,49379,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49379,1,3,0)
;;=3^Parkinson's Disease w/ Dementia w/ Bhv Dstrb
;;^UTILITY(U,$J,358.3,49379,1,4,0)
;;=4^G20.
;;^UTILITY(U,$J,358.3,49379,2)
;;=^5003770^F02.81
;;^UTILITY(U,$J,358.3,49380,0)
;;=G20.^^187^2447^25
;;^UTILITY(U,$J,358.3,49380,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49380,1,3,0)
;;=3^Parkinson's Disease w/ Dementia w/o Bhv Dstrb
;;^UTILITY(U,$J,358.3,49380,1,4,0)
;;=4^G20.
;;^UTILITY(U,$J,358.3,49380,2)
;;=^5003770^F02.80
;;^UTILITY(U,$J,358.3,49381,0)
;;=G31.01^^187^2447^26
;;^UTILITY(U,$J,358.3,49381,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49381,1,3,0)
;;=3^Pick's Disease
;;^UTILITY(U,$J,358.3,49381,1,4,0)
;;=4^G31.01
;;^UTILITY(U,$J,358.3,49381,2)
;;=^329915
;;^UTILITY(U,$J,358.3,49382,0)
;;=G23.1^^187^2447^28
;;^UTILITY(U,$J,358.3,49382,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49382,1,3,0)
;;=3^Progressive Supranuclear Ophthalmoplegia
;;^UTILITY(U,$J,358.3,49382,1,4,0)
;;=4^G23.1
;;^UTILITY(U,$J,358.3,49382,2)
;;=^5003780
;;^UTILITY(U,$J,358.3,49383,0)
;;=E11.21^^187^2448^33
;;^UTILITY(U,$J,358.3,49383,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49383,1,3,0)
;;=3^Type 2 DM w/ Nephropathy
;;^UTILITY(U,$J,358.3,49383,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,49383,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,49384,0)
;;=E11.22^^187^2448^31
;;^UTILITY(U,$J,358.3,49384,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49384,1,3,0)
;;=3^Type 2 DM w/ CKD
;;^UTILITY(U,$J,358.3,49384,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,49384,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,49385,0)
;;=E11.40^^187^2448^34
;;^UTILITY(U,$J,358.3,49385,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49385,1,3,0)
;;=3^Type 2 DM w/ Neuropathy,Unspec
;;^UTILITY(U,$J,358.3,49385,1,4,0)
;;=4^E11.40
;;^UTILITY(U,$J,358.3,49385,2)
;;=^5002644
;;^UTILITY(U,$J,358.3,49386,0)
;;=E11.65^^187^2448^32
;;^UTILITY(U,$J,358.3,49386,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49386,1,3,0)
;;=3^Type 2 DM w/ Hyperglycemia
;;^UTILITY(U,$J,358.3,49386,1,4,0)
;;=4^E11.65
;;^UTILITY(U,$J,358.3,49386,2)
;;=^5002663
;;^UTILITY(U,$J,358.3,49387,0)
;;=E11.9^^187^2448^35
;;^UTILITY(U,$J,358.3,49387,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49387,1,3,0)
;;=3^Type 2 DM w/o Complications
;;^UTILITY(U,$J,358.3,49387,1,4,0)
;;=4^E11.9
;;^UTILITY(U,$J,358.3,49387,2)
;;=^5002666
;;^UTILITY(U,$J,358.3,49388,0)
;;=E03.9^^187^2448^26
;;^UTILITY(U,$J,358.3,49388,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49388,1,3,0)
;;=3^Hypothyroidism
;;^UTILITY(U,$J,358.3,49388,1,4,0)
;;=4^E03.9
;;^UTILITY(U,$J,358.3,49388,2)
;;=^5002476
;;^UTILITY(U,$J,358.3,49389,0)
;;=N18.1^^187^2448^14
;;^UTILITY(U,$J,358.3,49389,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49389,1,3,0)
;;=3^Chronic Kidney Disease,Stage 1
;;^UTILITY(U,$J,358.3,49389,1,4,0)
;;=4^N18.1
;;^UTILITY(U,$J,358.3,49389,2)
;;=^5015602
;;^UTILITY(U,$J,358.3,49390,0)
;;=N18.2^^187^2448^15
;;^UTILITY(U,$J,358.3,49390,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,49390,1,3,0)
;;=3^Chronic Kidney Disease,Stage 2
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI33E 3777 printed Oct 16, 2024@18:41:48 Page 2
IBDEI33E ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,49378,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,49378,1,3,0)
+4 ;;=3^Frontotemporal Dementia NEC
+5 ;;^UTILITY(U,$J,358.3,49378,1,4,0)
+6 ;;=4^G31.09
+7 ;;^UTILITY(U,$J,358.3,49378,2)
+8 ;;=^329916
+9 ;;^UTILITY(U,$J,358.3,49379,0)
+10 ;;=G20.^^187^2447^24
+11 ;;^UTILITY(U,$J,358.3,49379,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,49379,1,3,0)
+14 ;;=3^Parkinson's Disease w/ Dementia w/ Bhv Dstrb
+15 ;;^UTILITY(U,$J,358.3,49379,1,4,0)
+16 ;;=4^G20.
+17 ;;^UTILITY(U,$J,358.3,49379,2)
+18 ;;=^5003770^F02.81
+19 ;;^UTILITY(U,$J,358.3,49380,0)
+20 ;;=G20.^^187^2447^25
+21 ;;^UTILITY(U,$J,358.3,49380,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,49380,1,3,0)
+24 ;;=3^Parkinson's Disease w/ Dementia w/o Bhv Dstrb
+25 ;;^UTILITY(U,$J,358.3,49380,1,4,0)
+26 ;;=4^G20.
+27 ;;^UTILITY(U,$J,358.3,49380,2)
+28 ;;=^5003770^F02.80
+29 ;;^UTILITY(U,$J,358.3,49381,0)
+30 ;;=G31.01^^187^2447^26
+31 ;;^UTILITY(U,$J,358.3,49381,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,49381,1,3,0)
+34 ;;=3^Pick's Disease
+35 ;;^UTILITY(U,$J,358.3,49381,1,4,0)
+36 ;;=4^G31.01
+37 ;;^UTILITY(U,$J,358.3,49381,2)
+38 ;;=^329915
+39 ;;^UTILITY(U,$J,358.3,49382,0)
+40 ;;=G23.1^^187^2447^28
+41 ;;^UTILITY(U,$J,358.3,49382,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,49382,1,3,0)
+44 ;;=3^Progressive Supranuclear Ophthalmoplegia
+45 ;;^UTILITY(U,$J,358.3,49382,1,4,0)
+46 ;;=4^G23.1
+47 ;;^UTILITY(U,$J,358.3,49382,2)
+48 ;;=^5003780
+49 ;;^UTILITY(U,$J,358.3,49383,0)
+50 ;;=E11.21^^187^2448^33
+51 ;;^UTILITY(U,$J,358.3,49383,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,49383,1,3,0)
+54 ;;=3^Type 2 DM w/ Nephropathy
+55 ;;^UTILITY(U,$J,358.3,49383,1,4,0)
+56 ;;=4^E11.21
+57 ;;^UTILITY(U,$J,358.3,49383,2)
+58 ;;=^5002629
+59 ;;^UTILITY(U,$J,358.3,49384,0)
+60 ;;=E11.22^^187^2448^31
+61 ;;^UTILITY(U,$J,358.3,49384,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,49384,1,3,0)
+64 ;;=3^Type 2 DM w/ CKD
+65 ;;^UTILITY(U,$J,358.3,49384,1,4,0)
+66 ;;=4^E11.22
+67 ;;^UTILITY(U,$J,358.3,49384,2)
+68 ;;=^5002630
+69 ;;^UTILITY(U,$J,358.3,49385,0)
+70 ;;=E11.40^^187^2448^34
+71 ;;^UTILITY(U,$J,358.3,49385,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,49385,1,3,0)
+74 ;;=3^Type 2 DM w/ Neuropathy,Unspec
+75 ;;^UTILITY(U,$J,358.3,49385,1,4,0)
+76 ;;=4^E11.40
+77 ;;^UTILITY(U,$J,358.3,49385,2)
+78 ;;=^5002644
+79 ;;^UTILITY(U,$J,358.3,49386,0)
+80 ;;=E11.65^^187^2448^32
+81 ;;^UTILITY(U,$J,358.3,49386,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,49386,1,3,0)
+84 ;;=3^Type 2 DM w/ Hyperglycemia
+85 ;;^UTILITY(U,$J,358.3,49386,1,4,0)
+86 ;;=4^E11.65
+87 ;;^UTILITY(U,$J,358.3,49386,2)
+88 ;;=^5002663
+89 ;;^UTILITY(U,$J,358.3,49387,0)
+90 ;;=E11.9^^187^2448^35
+91 ;;^UTILITY(U,$J,358.3,49387,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,49387,1,3,0)
+94 ;;=3^Type 2 DM w/o Complications
+95 ;;^UTILITY(U,$J,358.3,49387,1,4,0)
+96 ;;=4^E11.9
+97 ;;^UTILITY(U,$J,358.3,49387,2)
+98 ;;=^5002666
+99 ;;^UTILITY(U,$J,358.3,49388,0)
+100 ;;=E03.9^^187^2448^26
+101 ;;^UTILITY(U,$J,358.3,49388,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,49388,1,3,0)
+104 ;;=3^Hypothyroidism
+105 ;;^UTILITY(U,$J,358.3,49388,1,4,0)
+106 ;;=4^E03.9
+107 ;;^UTILITY(U,$J,358.3,49388,2)
+108 ;;=^5002476
+109 ;;^UTILITY(U,$J,358.3,49389,0)
+110 ;;=N18.1^^187^2448^14
+111 ;;^UTILITY(U,$J,358.3,49389,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,49389,1,3,0)
+114 ;;=3^Chronic Kidney Disease,Stage 1
+115 ;;^UTILITY(U,$J,358.3,49389,1,4,0)
+116 ;;=4^N18.1
+117 ;;^UTILITY(U,$J,358.3,49389,2)
+118 ;;=^5015602
+119 ;;^UTILITY(U,$J,358.3,49390,0)
+120 ;;=N18.2^^187^2448^15
+121 ;;^UTILITY(U,$J,358.3,49390,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,49390,1,3,0)
+124 ;;=3^Chronic Kidney Disease,Stage 2
